We are currently investigating Tasigna side effects cases as possible Tasigna drug injury lawsuits against Novartis for patients who have developed some serious medical conditions during their use of Tasigna.
In early June 2021, the New Jersey Supreme Court consolidated Tasigna drug injury lawsuits filed against Novartis Pharmaceuticals Corp. before one judge for pretrial proceedings as part of a New Jersey state court multi-county litigation (MCL). And in July 2021 the U.S. Judicial Panel on Multidistrict Litigation (JPML) is expected to hear arguments in support of a request that all Tasigna drug injury lawsuits filed in the U.S. federal court system be consolidated as a Tasigna multidistrict litigation (MDL). All of these Tasigna lawsuits involve alleged Tasigna side effects suffered by patients.
Tasigna has been linked to atherosclerosis, which is a disease that results in thickening, hardening, and blocking of the arteries due to the buildup of plaque. In turn, strokes, heart attacks, and lower limbs amputations can be Tasigna side effects as these are serious medical conditions that can result from, or are secondary to, atherosclerosis-related diseases.
In more detail, the following medical conditions are considered to be atherosclerosis-related diseases:
- peripheral arterial disease (PAD) involving lower limbs;
- peripheral arterial occlusive disease (PAOD);
- ischemic heart disease; and
- ischemic cerebrovascular disease.
As background, in Canada the drug company Novartis Pharmaceuticals has issued stronger warnings about atherosclerosis-related diseases being Tasigna side effects — compared to what is found on the US version of the Tasigna drug label. This situation has given rise to the contention that warnings about Tasigna side effects in the current US drug label are insufficient, or a failure to adequately warn. In turn, Tasigna drug injury lawsuits have been filed against Novartis here in the U.S.[Read article in full at original source]